Lethal neonatal bone marrow failure syndrome with multiple congenital abnormalities, including limb defects, due to a constitutional deletion of 3’ MECOM by Veken, L.T. (Lars) van der et al.
Lethal neonatal bone marrow failure syndrome with
multiple congenital abnormalities, including limb
defects, due to a constitutional deletion of 3’
MECOM
EVI1 (3q26.2) is a member of the SET/PR domain fam-
ily of transcription factors and contains two domains of
zinc finger (ZF) DNA binding motifs, one at the N-termi-
nus (ZF1) and one at the C-terminus (ZF2), and a C-ter-
minal acidic amino acid cluster domain (AD). The
MDS1/EVI1 locus gives rise to alternatively spliced vari-
ants, including intergenic MDS1 EVI1 complex
(MECOM) splicing. EVI1 is pivotal in leukemogenesis
and mammalian development. EVI1 over-expression is
associated with the development and progression of
high-risk acute myeloid leukemia (AML). EVI1/MECOM
is a transcriptional regulator essential for maintaining
embryonic and adult hematopoietic stem cells (HSCs) by
directly regulating transcription of GATA2. In mouse
models, homozygous disruption of Evi1 results in embry-
onic lethality, with hypocellular bone marrow, reduced
body size, small or absent limb buds, and abnormal
development of the nervous system. Evi1+/- mice showed
an intermediate phenotype compared to Evi1-/- mice both
in fetal liver (FL) hematopoiesis as well as in adult
hematopoiesis, suggesting a Evi1 gene dosage require-
ment in the regulation of HSCs.1
To date, two case reports have been published on het-
erozygous copy number abnormalities (CNA) affecting
MECOM. One patient, presenting with congenital
thrombocytopenia, had a deletion which included the
entire MECOM locus.2 A second newborn presenting
with respiratory problems, low birthweight, congenital
thrombocytopenia, and slight facial dysmorphisms, had a
deletion of the first two exons of MDS1.3 Furthermore,
heterozygous missense single nucleotide variations
(SNVs) within the eighth zinc finger motif of ZF2 of
MECOM were published in three simplex cases with
radioulnar synostosis with amegakaryocytic thrombocy-
topenia (RUSAT [Online Mendelian Inheritance in Man:
065432]), an inherited bone marrow failure (BMF) syn-
drome with skeletal anomalies.4 Very recently, Ripperger
et al. reported on a three generation familial SNV affect-
ing the ninth zinc finger motif of ZF2 in four members
with limb dysmorphisms, and thrombocytopenia in one
member. Interestingly, two affected family members
developed myeloid neoplasia later in life.5 Furthermore,
of late Bluteau et al. described six simplex cases; three
with mutations affecting ZF2 and three with frameshift
mutations, all associated with hypocellular bone marrow,
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Figure 1. Cranial MRI and X-ray images of hand
and foot of a neonate with syndromic BMF asso-
ciated with interstitial 3’MECOM deletion. (A) T1-
weighted sagittal (left) and T2-weighted axial
(right) cranial MRI showing enlarged extracerebral
cerebrospinal fluid spaces, and reduced frontal
gyrification for the developmental stage (gesta-
tional age at birth 38+5 weeks, MRI day 6). (B) X-
ray images of left foot showing clubfeet, and (C) a
short fifth middle phalanx of the right hand.
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Figure 2. Heterozygous copy number loss of 3’MECOM as a result of an interstitial deletion in 3q26.2 in a neonate with syndromic BMF. (A) Chromosome 3 is
shown, and detailed depiction of the affected area, demonstrating heterozygous 3q26.2 3’MECOM copy number loss (in red). SNP-array copy number profiling
and analysis of regions of homozygosity were performed on DNA isolated from peripheral blood according to standard procedures using the Infinium Human
CytoSNP-850K v1.1 BeadChip (Illumina, San Diego, CA, USA). Subsequently, visualizations of SNP-array results and data analysis were carried out using
NxClinical software v3.0 (BioDiscovery, Los Angeles, CA, USA). Human genome build Feb. 2009 GRCh37/hg19 was used. Results were classified with BENCH
Lab CNV software (Agilent, Santa Clara, CA, USA). (B) Schematic representation of the chromosome 3q26.2 MECOM region. The bar with whiskers represents
the 854 kb deletion encompassing the EGFEM1P and EVI1 (partially) genes. Highlighted is the breakpoint at chromosomal position 167.962.667 upstream of
the gene EGFEM1P and at chromosomal position 168.816.688 between exons 11 and 12 of MECOM (hg19/GRCh37) by captured sequencing (as described
in10). Breakpoint sequence post-deletion is provided. Localization of the MECOM triple color FISH probe. Representation of EVI1 protein. Map not drawn to scale.
Chr: chrosome; FISH: fluorescence in situ hybridization; ZF: zinc finger; BAF: B allele frequency.
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but some also had congenital limb defects.6
We report on the third patient, a neonate born with
skeletal and neurological abnormalities and hypocellular
bone marrow, with a constitutional copy number alter-
ation in MECOM, particularly the first one with a dele-
tion affecting only the 3’ part of MECOM. The ~854 kb
deletion resulted in loss of 3’ MECOM exons, encoding
the ZF2 and AD. We will discuss the genetic and clinical
heterogeneity of these cases with MECOM abnormalities
associated with BMF with or without additional congen-
ital anomalies.
A male neonate was born with severe congenital
abnormalities and apparent BMF. He was the fourth child
of non-consanguineous parents. The couple had three
healthy daughters and no history of miscarriages.
Prenatal ultrasounds from 20 weeks gestation onward
had shown club feet and polyhydramnios, but normal
growth. The patient was born, with respiratory failure, at
a gestational age of 38+5 weeks. The placental examina-
tion was unremarkable. Clinical examination showed
macrocephaly, but otherwise only minor facial dysmor-
phisms. There was an ulnar deviation of the right hand
(the left hand could not be evaluated). The lower extrem-
ities showed no abnormalities other than club feet. His
hair and nails were normal. Laboratory evaluation
showed pancytopenia. Flow cytometry only showed
naïve CD4+ and CD8+ T cells with normal T-cell receptor
Vβ chain distribution. Therefore, there was no sign of
malignant monoclonal hematopoiesis. Bone marrow was
hypocellular. A cranial ultrasound performed directly
after birth showed subnormal gyrification for the gesta-
tional age, wide peripheral cerebrospinal fluid spaces and
fissures and a large cavum of the septum pellucidum
(Figure 1A). A skeletal evaluation showed club feet and a
short fifth midphalanx of the right hand  (Figure 1B,C).
The cardiac ultrasound examination was normal. The
patient died of infections and anemia at 25 days after
birth. There was no consent for postmortem evaluation
(see Online Supplementary Table S1 for detailed clinical
and laboratory characteristics).
Chromosome analysis on phytohaemaglutin-stimulat-
ed T-lymphocytes from peripheral blood resulted in a
46,XY karyotype. Single nucleotide polymorphism
(SNP)-array analysis  on DNA isolated from peripheral
blood revealed a male array profile with heterozygous
copy number loss within chromosome 3 band q26.2 of a
minimal size of 841 kb, deleting 3’ terminal exons 12 to
17 of MECOM (arr[GRCh37]
3q26.2[167974061_168815099]x1 [International System
for Human Cytogenomic Nomenclature [ISCN] 2016])
(Figure 2A). Targeted next-generation sequencing (NGS)
of the 3q26.2 region located the exact breakpoints of the
854 kb deletion at chromosomal position 167.962.667
(proximal breakpoint), and at chromosomal position
168.816.688 within intron 11 of MECOM, resulting in
the loss of coding exons 12 to 17, affecting ZF2 and AD
domains (Figure 2B). Via fluorescence in situ hybridization
(FISH) analyses on peripheral blood the deletion was con-
firmed and its constitutional nature was demonstrated on
skin fibroblasts and buccal swabs (46,XY.ish
3 q 2 6 . 2 [ 3 ’ M E C O M - , 5 ’ M E C O M + ] . n u c
ish[3’MECOMx1,5’MECOMx2] [ISCN 2016]) (Figure 3).
Neither targeted NGS, nor Sanger sequencing of the cod-
ing region of MECOM using intronic primers, indicated
any additional circulating nucleic acids or sequence vari-
ants within MECOM. The coding regions of GATA2 and
RUNX1 genes were investigated by Sanger sequencing
using intronic primers, revealing no SNV or
insertion/deletion. The intronic enhancer of GATA2 was
not investigated. Cultured lymphocytes from peripheral
blood did not show increased sensitivity for mitomycin
C, and as such did not positively identify the patient with
Fanconi anemia. Karyotyping and FISH analyses of
peripheral blood of both parents did not reveal a structur-
al or numerical abnormality of MECOM, indicating the
deletion to be de novo.
Of note are the resemblances of a RUSAT-like pheno-
typic presentation in the cases as described by Niihori 
et al., Ripperger et al., Bluteau et al.4-6 and the present case.
The constitutional nature of the published SNVs within
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Figure 3. FISH analyses demonstrating constitutional 3’MECOM deletion in
syndromic BMF. (A) Triple color FISH analyses demonstrating loss of proximal
3’MECOM signal (green) on one of two paired metaphase chromosome 3
homologues, and one interphase nucleus (phytohaemaglutin-stimulated
peripheral blood T-lymphocytes), and (B) on one of two paired metaphase
chromosome 3 homologues (cultured skin fibroblasts), and (C) on one inter-
phase nucleus (buccal mucosa), using 3q26.2 MECOM probe on EVI
t(3;3);inv(3)(q26) Break, TC (Kreatech, Rijswijk, The Netherlands). For
metaphases the individual signals of the triple color probe combination are
shown separately. Arrows in interphases point to loss of one green proximal
3’MECOM signal. Images represent all analyzed cells (10 metaphases and
200 interphase nuclei of T-lymphocytes, 10 metaphases of cultured skin
fibroblasts, and 200 interphase nuclei of buccal mucosa). FISH: fluorescence
in situ hybridization.
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MECOM, and the deletion in the present case, affecting
the ZF2 domain encoding exons of MECOM, are in
strong support of their pathogenicity. Of similar distinc-
tion is the resemblance in the phenotypic presentation of
our case and Evi1-deficit mouse models. Evi1-/- mice die
during embryogenesis due to bone marrow hypocellular-
ity. Embryos show defects in the heart, cranial ganglia
and the peripheral nervous system with small dorsally
positioned forelimb buds.7,8
Notably, the two previously reported cases with a dele-
tion show some differences in the severity of clinical
manifestation. The first presented with isolated throm-
bocytopenia at birth, progressing to pancytopenia with
aplastic bone marrow at two months of age, requiring
allogeneic stem cell transplantation, but without overt
congenital malformations.2 As one entire copy of
MECOMwas lost, the phenotype can be due to MECOM
haploinsufficiency, resembling Mecom+/- mice models in
some instantances. The second newborn presented with
low birthweight, facial anomalies and a submucosal cleft
palate, a small ventricular septal defect and thrombocy-
topenia.3 There was no information on malformation of
the extremities. The patient died 28 days after birth due
to respiratory insufficiency. Bouman et al. hypothesized
that the hematological phenotype could also be due to
haploinsufficiency of MECOM. Nevertheless, as only the
first two exons of MDS1were deleted, the authors stated
that this could still allow EVI1 expression because of
alternative transcription starting sites. Therefore, one
cannot rule out negative interference with normal
MECOM function. 
Available data do not allow for a conclusion as to
whether in the present case the 3’MECOM deletion
would result in MECOM haploinsufficiency by messen-
ger ribonucleic acid (mRNA) decay, or in dominant inter-
ference by a structurally aberrant protein. It has been
reported that EVI1 oligomerization is not impaired by C-
terminal truncated EVI1 protein in vitro.9 One could thus
hypothesize that in the present case a C-terminally-
affected EVI1 oligomerizes with EVI1, thereby tethering
EVI1 protein-mediated transcriptional regulation of
GATA2 even below the level of 50%, as can be expected
in the case of a loss of one MECOM allele as described by
Nielsen et al., resulting in a more dramatic perturbation of
HSC homeostasis (threshold model). This would be a
plausible explanation for the difference in severity of the
phenotype of our case, the embryonic lethality in 
Evi1- or Gata2-deficient mouse models, and the pheno-
type of Evi1+/- mice or the case with a heterozygous
deletion spanning MECOM. One also has to consider the
possibility of mosaicism, which could reflect divergence
in phenotypic presentation. As EVI1mRNA expression is
not restricted to the hematopoietic system, a direct dele-
terious effect of the EVI1 anomaly in other tissues seems
likely. The data on the cases with MECOM SNV’s as well
as the present case indicate that the mutation was pres-
ent at conception, or occurred during (early) postzygotic
isolation. In the two other cases with a deletion affecting
MECOM, no data were available on its status in non-
hematopoietic cells. Given their phenotypic presenta-
tions one could also argue mosaicism in these latter
cases.
In conclusion, we report on the third case of BMF syn-
drome associated with a constitutional CNA in MECOM,
particularly the first one with a deletion affecting the 3’
part of MECOM, presenting, however, with multiple
congenital anomalies, including limb defects. Together
with all reported cases on CNA and SNV of MECOM it
clearly establishes MECOM as a recurrent causative gene
in (syndromic) BMF. Therefore, one should consider, in
case of neonatal thrombocytopenia with or without
other dysmorphisms, investigating the MECOM locus for
CNAs and SNVs. The syndrome appears to present with
variable severity of phenotypic manifestations that might
be due to the nature of the MECOM abnormality.
Furthermore, investigation of tissues other than the
hematopoietic system, together with the consequences
both at the transcriptional and post-transcriptional level
would greatly contribute to our understanding of the
pathogenic mechanism(s).
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